Nelly Shishkova

XenoPort, Inc. (NASDAQ:XNPT) Starts The Gain

by Nelly Shishkova July 26, 2010

Watch the video to learn about the probability of XenoPort, Inc. (XNPT) Chart Signal as of May 06, 2016

This free program will calculate the probabilities of XenoPort, Inc. (XNPT) stock chart

Rating: Platform: Win/Mac
Price: FREE Version: 1.1
Size: 656KB Downloads: 800,000+
FREE DOWNLOAD
Last Friday, XenoPort, Inc. (NASDAQ:XNPT) started to gain on the market. The stock soared 2.42% on its price to close at image133.png$6.34 per share and its volume exceeded 525 thousand shares traded.

The reason for the climb appeared to be the recent announcement by the company about its new prodrug. After the announcement was published, the investors got excited and XNPT started to climb up. However, nobody knows if it's going to be a bullish trend or just a high momentum.

The latest quarterly results of XNPT are scheduled to be presented in ten days and the analysts expect losses to be reported. Though, the actual results are up to be seen.

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of proprietary product candidates, which utilizes the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.

According to the historical data, the company has traded much higher during the last 12 months. Last September XNPT traded at $25.00 per share, but since then the price has moved down. This February the traded volume reached over 30 million shares and provided for profits. While presently the price is going up again, though at a lower level.

XNPT_logo.gifThis month, XNPT made a few more optimistic announcements, though the  stock price has fallen down over 26% and it was pointed among the top 10 largest percentage decreases on NASDAQ.

In its fist quarter report for this year XenoPort states that: "Due to our significant research and development expenditures and the lack of regulatory agency approvals to sell products, we have generated cumulative operating losses", though it claims that XNPT's "existing capital resources, together with interest thereon, will be sufficient to meet our projected operating requirements into the first quarter of 2012".

The company has generated a higher net income, though it reported that if any additional financing is needed, the company may: "terminate or delay clinical trials for one or more of our product candidates".

Presently, XNPT relies on its novel prodrug to be approved, though no one can be certain for the future results yet.

Watch the video to learn about the probability of XenoPort, Inc. (XNPT) Chart Signal as of May 06, 2016

Hotstocked Precision will calculate the probabilities of XenoPort, Inc. (XNPT)

Rating:
Size: 656KB
Version: 1.1
Platform: Win/Mac
Downloads: 800,000+
FREE DOWNLOAD

Comments 3

1. Guest
November 28, 2015, 04:43AM

Quotes Grazie mille Gooser,quindi provando a bttraue una strategia ed immaginando il suo anno come il 2014, se dovesse salire in prossimite0 di ASCO ci starebbe vendere prima dell'evento per poi pensare di entrare con pif9 calma dopo, che ne pensate?Matteo

2. Guest
November 26, 2015, 11:18AM

Quotes , trimestrale nelle asaittpteve. Da queste poche righe non si capisce quante azioni sono state vendute a mercato e viene sempre confermata l'attesa di una risposta da parte di FDA per il proseguimento dello studio clinico in corso. Voglio sentire prima pero' tutta la conference per un'idea pif9 completa sopratutto sui nuovi studi clinici che potrebbero partire prossimamente. Confermo comunque che il titolo e8 tra i pif9 interessanti secondo me.

3. Guest
November 26, 2015, 02:57AM

Quotes , Rispondo ad alessio ma vale per tutti eh (giorgio riosdnpo alla tua e-mail qui)ACHN: i motivi per cui e8 scesa sono fondamentalmente 2. Primo si aspettava un accordo con qualche grossa biotech che fino ad ora non e8 arrivato. Secondo gli ottimi dati della concorrenza che sono usciti di recente.Detto questo ACHN resta l'unica piccola biotech ancora appetibile da qualche grande. (BRCX al momento mi sento di metterla da parte).Sulla carta il loro farmaco sembra inferiore alla concorrenza ma non e8 detto che lo sia realmente (vedi i dati rilasciati da Abbott con il loro farmaco). L'azienda e8 impegnatissima con 2 phase 2 e 2 phase 1 se ricordo bene.Cosa ancora pif9 importante e8 che la concorrenza e8 impegnatissima i passi falsi degli altri potrebbe avvantaggiare ACHN. (non parlo di Gilead ovviamente).Riguardo ad un'acquisto terrei molto d'occhio l'at per capire fino a quando ci sare0 la pressione dei bearish. Quando finire0 forse un ingresso ci potre0 stare.

Type the characters that you see in the box (5 characters).